Nkarta Inc
$ 2.29
0.00%
14 Apr - close price
- Market Cap 163,255,000 USD
- Current Price $ 2.29
- High / Low $ 2.42 / 2.28
- Stock P/E N/A
- Book Value 4.39
- EPS -1.41
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.29 %
- 52 Week High 2.81
- 52 Week Low 1.63
About
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
Analyst Target Price
$14.20
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-26 | 2025-11-05 | 2025-08-12 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.37 | -0.29 | -0.31 | -0.43 | -0.35 | -0.39 | -0.34 | -0.58 | -0.57 | -0.52 | -0.6 | -0.63 |
| Estimated EPS | -0.295 | -0.338 | -0.35 | -0.45 | -0.4 | -0.36 | -0.45 | -0.56 | -0.59 | -0.67 | -0.68 | -0.7 |
| Surprise | -0.075 | 0.048 | 0.04 | 0.02 | 0.05 | -0.03 | 0.11 | -0.02 | 0.02 | 0.15 | 0.08 | 0.07 |
| Surprise Percentage | -25.4237% | 14.2012% | 11.4286% | 4.4444% | 12.5% | -8.3333% | 24.4444% | -3.5714% | 3.3898% | 22.3881% | 11.7647% | 10% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.37 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NKTX
2026-04-09 17:39:14
Nkarta, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference. CEO Paul Hastings will join a virtual panel discussion on "Cell Therapy in Autoimmune: State of the Art and What Comes Next," and President Nadir Mahmood will provide updates on the company’s investigational CAR-NK cell therapy. A webcast of the fireside chat will be available on Nkarta's investor website.
2026-04-09 17:09:43
Nkarta, Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference. CEO Paul Hastings will join a virtual panel discussion on cell therapy in autoimmune diseases, while President Nadir Mahmood will lead a fireside chat discussing updates on the company's investigational CAR-NK cell therapy. A webcast of the fireside chat will be available on Nkarta's website.
2026-04-09 11:39:52
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company focused on engineered natural killer (NK) cell therapies for autoimmune diseases, announced its participation in the 25th Annual Needham Virtual Healthcare Conference. CEO Paul Hastings will join a panel discussion on "Cell Therapy in Autoimmune" on April 15, and later that day, President Nadir Mahmood will discuss the company's investigational CAR-NK cell therapy in a fireside chat. A webcast of the fireside chat will be available on Nkarta's investor relations website.
2026-04-09 10:39:52
Nkarta (Nasdaq: NKTX) announced its participation in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. CEO Paul Hastings will join a panel discussion on cell therapy in autoimmune diseases, and President Nadir Mahmood will deliver a fireside chat providing updates on the company's investigational CAR-NK therapy for B cell-mediated autoimmune diseases. A webcast of the fireside chat will be available on Nkarta's Investors website and archived for approximately 90 days.
2026-04-06 06:39:26
Nkarta, Inc. (NASDAQ:NKTX) has an average "Hold" recommendation from five brokerages, with an average 12-month price target of $11.33. The company recently missed its EPS estimates and its CEO, Paul J. Hastings, sold 26,046 shares in January. Institutional investors hold a significant portion of the stock, while its shares currently trade around $2.32.
2026-04-06 04:39:26
This article reports on an SEC filing by Nkarta, Inc. (NKTX) for a Form EFFECT, which became effective on April 3, 2026, at 4:00 P.M. The filing is identified as an S-3 form related to shelf registration. The article also provides Nkarta's stock overview, recent news, and other SEC filings.
